Advanced Enzyme Technologies Ltd — Q4 FY26
Advanced Enzyme delivered a record quarter with revenue of ₹203.4 crore (+22% YoY) and EBITDA of ₹63.2 crore (+39% YoY), driven by strong volume growth in human healthcare (up 2...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Tariff impact on EBITDA margin ~1%
Worst-case tariff impact on EBITDA margin expected to be around 1% (down from earlier 2% estimate), with efforts to pass on costs to US customers.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
B2C business to generate ₹1-1.5 crore in FY26
The newly separated B2C subsidiary is expected to achieve small sales of around ₹1-1.5 crore by end of current fiscal year.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1